Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Maryam Zanjirband; Nicola Curtin; Richard J. Edmondson; John Lunec

doi:10.18632/oncotarget.28523

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

PDF | How to cite

Oncotarget. 2024; 15:142-142. https://doi.org/10.18632/oncotarget.28523

Metrics: PDF 1046 views | ?

Maryam Zanjirband¹, Nicola Curtin¹, Richard J. Edmondson² and John Lunec¹

¹Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE2 4HH, United Kingdom
²Faculty Institute for Cancer Sciences, University of Manchester, Manchester M13 9WL, United Kingdom

Published: February 22, 2024

Copyright: © 2024 Zanjirband et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 5, the actin band in the A2780 column contains a partial duplicate of the same band in the IGROV-1 column. The corrected Figure 5, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:69779–69796. DOI: https://doi.org/10.18632/oncotarget.19266

Figure 5: Combination of Nutlin-3/RG7388 with rucaparib increased upregulation of TP53 downstream target, PUMA compared to rucaparib on its own but not compared to Nutlin-3/RG7388. Total levels of PUMA 24 hours after the commencement of treatment with Nutlin-3 and RG7388 alone, and in combination with rucaparib at constant 1:1 ratios of 1X their respective GI₅₀ concentration analyzed by western blot in three wild-type TP53 ovarian cancer cell lines.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28523

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer